• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Xbrane Biopharma

10.75 SEK

+4.37 %

Less than 1K followers

XBRANE

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+4.37 %
-6.11 %
+80.73 %
+5.39 %
-0.11 %
-63.59 %
-99.02 %
-99.53 %
-97.75 %

Xbrane Biopharma is a biotechnology company focused on the development of biosimilars and biologics. The company is researching new therapies that can improve patient outcomes and quality of life. The products are used in the treatment of prostate cancer and endometriosis, as well as rare and serious eye diseases. Xbrane Biopharma was founded in 2008 and is headquartered in Solna, Sweden.

Read more
Market cap
221.51M SEK
Turnover
228.9K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Forum discussions
Quite a struggle. A trainwreck, as they would say across the pond. Once again, additional information must be provided to the FDA, and the BLA has been withdrawn. An additional delay of approximately 6–12 months is expected AND even more capital may potentially be needed. For fun...
4/23/2024, 7:25 AM
by vesuri
7
xbrane.com » Xbrane and STADA partner with Valorum Biologics to commercialize... XBRANE AND STADA PARTNER WITH VALORUM BIOLOGICS TO COMMERCIALIZE RANIBIZUMAB BIOSIMILAR CANDIDATE IN THE US Based on this, could one think that obtaining FDA approval looks quite promising?
5/10/2024, 7:13 AM
by OSAKEURPO
4
Xbrane warns that it will be insolvent in a couple of months if the desired financing solutions are not reached and the company does not manage to out-license the Xdivane™ and/or XB003 candidates by the end of October. As communicated on 1 August 2024 and given the previously communicated...
8/12/2024, 11:38 AM
by vesuri
3
It’s frustrating when the reverse split isn’t properly taken into account. But that company’s journey is still not amounting to anything.
10/22/2025, 12:03 PM
by Clark kent
1
It’s hard to see any profitable future for this Ximluci. From what I’ve researched, off-label Bevacizumab is still cheaper, and on the other hand, aflibercept and faricimab are better and longer-acting. There simply isn’t a market niche.
5/10/2024, 7:34 AM
by Clark kent
1
The share price has started to wake up in recent days. Apparently in anticipation of FDA approval in April.
4/8/2024, 3:07 PM
by OSAKEURPO
1
I haven’t really followed this, but big gainers and losers are always interesting. So, a 343Mkr rights issue is being proposed for a company whose market cap fell 75% today (at the time of writing) to a market cap of 57Mkr. The rights issue will only take place after the Extraordinary...
1/22/2024, 1:46 PM
by Expaco_b
1
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17.7.
2026

Interim report Q2'26

30.10.
2026

Interim report Q3'26

19.2.
2027

Annual report '26

Xbrane Biopharma, Webcast, Q2'26
Webcast7/17/2026, 7:00 AM

Xbrane Biopharma, Webcast, Q2'26

Xbrane Biopharma
Regulatory press release6/11/2026, 6:00 PM

Xbrane Biopharma AB and JOINN Biologics US Inc. Enter Strategic Partnership to Develop Xdarzane – Xbrane´s Biosimilar Candidate to Darzalex® (Daratumumab)

Xbrane Biopharma
Regulatory press release6/3/2026, 4:00 PM

Xbrane Biopharma AB (publ) (“Xbrane” or “the Company”) (Nasdaq Stockholm: XBRANE) receives FDA BsUFA date of October 29, 2026 for its investigational biosimilar candidate to LUCENTIS® (ranibizumab)

Xbrane Biopharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release5/11/2026, 8:26 AM

Redeye: Xbrane Biopharma (Q1 review): Funding outlook improved, FDA decision in November

Xbrane Biopharma
Regulatory press release5/5/2026, 3:30 PM

Announcement from the annual general meeting in Xbrane Biopharma AB

Xbrane Biopharma
Xbrane Biopharma, Webcast, Q1'26
Webcast5/5/2026, 7:00 AM

Xbrane Biopharma, Webcast, Q1'26

Xbrane Biopharma
Regulatory press release5/5/2026, 6:00 AM

Xbrane Biopharma AB’s (publ.) (”Xbrane”) Interim Report January-March 2026, is as of today, available on the Company’s website, www.xbrane.com.

Xbrane Biopharma
Regulatory press release5/5/2026, 5:00 AM

Valuation expert Venture Valuation provides external valuation of Xdivane program

Xbrane Biopharma
Regulatory press release5/5/2026, 5:00 AM

Xbrane and its partner Intas agree on revised financing arrangement for Xbrane’s Xdivane development activities

Xbrane Biopharma
Regulatory press release4/30/2026, 6:00 AM

XBRANE SUBMITS RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA

Xbrane Biopharma
Regulatory press release3/31/2026, 4:00 PM

Xbrane provides an update on the timeline for resubmission of the market authorization application in the United States

Xbrane Biopharma
Regulatory press release3/31/2026, 8:00 AM

NOTICE OF ANNUAL GENERAL MEETING IN XBRANE BIOPHARMA AB

Xbrane Biopharma
Regulatory press release3/31/2026, 8:00 AM

Xbrane has released the company's 2025 Annual and Sustainability Report. The report summarizes business, financial performance and work on sustainability.

Xbrane Biopharma
Press release2/23/2026, 10:44 AM

Redeye: Xbrane Biopharma (Q4 review): Challenging outlook

Xbrane Biopharma
Xbrane Biopharma, Webcast, Q4'25
Webcast2/20/2026, 8:00 AM

Xbrane Biopharma, Webcast, Q4'25

Xbrane Biopharma
Regulatory press release2/20/2026, 7:00 AM

Xbrane Biopharma releases Year-end Report 2025

Xbrane Biopharma
Press release2/13/2026, 7:00 AM

Invitation to presentation of Xbrane Biopharma’s Year-end report 2025 on February 20, 2026

Xbrane Biopharma
Regulatory press release11/24/2025, 4:30 PM

Xbrane Biopharma resolves to issue 420,517 warrants to Fenja Capital II A/S under the conditional financing solution

Xbrane Biopharma
Regulatory press release11/19/2025, 7:00 AM

XBRANE UPDATES ON TIMING FOR RESUBMISSION OF THE BLA FOR ITS RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA

Xbrane Biopharma
Press release11/4/2025, 12:50 PM

Redeye: Xbrane Biopharma (Q3 update) - Headwinds have continued

Xbrane Biopharma